Form 4: Twist Bioscience Executive Sells Shares for Tax Withholding

Dennis Cho, Senior Vice President at Twist Bioscience, sold shares to cover tax obligations related to vested Restricted Stock Units.

Summary

• Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary of Twist Bioscience Corp., reported a transaction on June 22, 2026.
• The transaction involved the sale of 346 shares of common stock at a price of $87.32 per share.
• This sale was conducted to cover tax withholding obligations upon the vesting of Restricted Stock Units (RSUs).
• The company's equity incentive plans mandate a 'sell to cover' transaction for satisfying tax withholding requirements.
• Following this transaction, Dennis Cho beneficially owns 119,346 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the transaction is a routine, mandated event for tax purposes and does not reflect a discretionary decision by the executive regarding the company's prospects.

Negatives

• The sale of shares by an executive, even for tax purposes, can sometimes be perceived negatively by the market, although this specific transaction is mandated by company policy.

Risks

• The filing does not explicitly mention any new risks. However, the reliance on 'sell to cover' transactions for tax obligations implies that executives may not always retain the full number of vested shares, which could be a consideration for their personal equity stake.

Future Outlook

This filing is a report of a past transaction and does not contain forward-looking statements or guidance regarding the company's future financial performance.

Management Comments

• The sale of 346 shares was required to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.
• These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a 'sell to cover' transaction and do not represent discretionary trades by the Reporting Person.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard for executives and directors reporting changes in their beneficial ownership of company stock. The 'sell to cover' mechanism for tax withholding is a common practice in the biotech and technology sectors, particularly when stock-based compensation is a significant part of executive remuneration.

Stakeholder Impact

• Shareholders: The sale is a pre-planned event to cover taxes and is not indicative of a change in the executive's confidence in the company. The impact on share price is expected to be minimal.
• Employees: This filing highlights the company's use of stock-based compensation and the associated tax implications, which is relevant to employees who also receive equity awards.
• Management: The transaction confirms the standard operating procedure for managing tax liabilities related to equity compensation.

Key Dates

Keywords

Form 4, SEC Filing, Twist Bioscience, TWST, Stock Sale, Tax Withholding, Restricted Stock Units, Executive Transaction, Beneficial Ownership